An observational study in Cutaneous T-cell Lymphoma, Sezary Syndrome and Mycosis Fungoides, sponsored by University of Pittsburgh. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by University of Pittsburgh · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States — 33 open to participants now, 45 under way, none of them phase 3. Lymphoma, T-Cell, Cutaneous · United States.
Among the 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States, this one is the 13th largest by planned enrollment of the 41 observational ones that give a count, is one of 22 that started in 2004, is one of 41 observational ones, reaches primary completion later than 35 of the 43 other live ones, and was the 147th registered.
554 studies on the registry are indexed under Lymphoma, T-Cell, Cutaneous; 63 are open to participants now.
Browse Lymphoma, T-Cell, Cutaneous studies →33 of the 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States are open now. Recruiting first, the newest first:
Kyowa Kirin, Inc. · Sites in United States, Italy, Spain
Ages 18+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 2 more countries
Ages 18+
Seda S. Tolu · Sites in United States
Ages 18–95
Mayo Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 44 Lymphoma, T-Cell, Cutaneous studies recruiting now, 33 (75%) set no upper age limit and 6 (14%) stop at 75 or younger; 5 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
434 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 201 · Phase 2 157 · Phase 3 28 · Phase 4 5
First in 1988; this study’s year is marked. 22 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 120 across 59 observational studies indexed under Lymphoma, T-Cell, Cutaneous.
Median enrollment 33 across the 334 interventional studies, 60 across the 41 observational. Of the 359 that completed or were terminated, 115 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
78 of 434 have an industry lead sponsor. The 10 most frequent:
University of Pittsburgh is the lead sponsor of 1,422 studies on the registry; 170 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
University of Pittsburgh has 4 studies filed under Lymphoma, T-Cell, Cutaneous — fewer than ten, so there is no comparison to draw.
13 of the studies in Lymphoma, T-Cell, Cutaneous with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05996185Yale UniversityStudy of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma | 2026-11 |
| NCT05956041University of Michigan Rogel Cancer CenterPembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas | 2026-12 |
| NCT06860880UNC Lineberger Comprehensive Cancer CenterCombating Cancer-Related Fatigue: A Personalized Supportive Care Program | 2026-12-31 |
| NCT05296304Memorial Sloan Kettering Cancer CenterA Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides | 2027-03 |
| NCT05680558Columbia UniversityPhotopheresis in Early-stage Mycosis Fungoides | 2027-03 |
Add all 13 to your calendar (.ics) → With an account.
Among the 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.
The purpose of this study is to provide a central mechanism for monitoring access to peripheral blood, urine, and skin specimens obtained from CTCL, eczema, and atopic dermatitis patients to monitor:
Subjects with cutaneous t-cell lymphoma and/or Sezary syndrome and atopic dermatitis or eczema patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Those subjects with cutaneous t-cell lymphoma and Sezary syndrome, atopic dermatitis, or eczema may participate as appropriate with the potential for blood, tissue or urine sampling.
Other: Blood draw, skin biopsy or urine collection
Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.
Proteomics of Cutaneous T-cell lymphoma
Proteomic variables will be measured in blood and tissue of consented CTCL patients.
Time frame: Ongoing
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2004 (actual). Primary completion is estimated for Jan 2030, 303 months after the start.
Of 23 observational studies under Lymphoma, T-Cell, Cutaneous, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 26. This study's planned 303 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.